rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.

Dan LiTianyuzhou LiangLaura E HutchinsAlexandra A WolfarthSara Ferrando-MartinezByung Ha LeeMitchell Ho

Published in: Journal for immunotherapy of cancer (2024)

This study provides a rationale for NT-I7 plus CAR-T cell combination therapy for solid tumors in humans.

Keyphrases